Skip to main content

Vivos Therapeutics, Inc.

corporate_fare Company Profile

Vivos Therapeutics, Inc.

VVOS·NASDAQ·Industrial Applications And Services·CIK 0001716166

Vivos Therapeutics, Inc. is a revenue stage medical technology and healthcare services company that provides a comprehensive suite of proprietary oral appliances and therapeutic treatments. The company's products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws linked to breathing and sleep disorders, including mild to severe obstructive sleep apnea (OSA) and snoring in adults. This approach, called The Vivos Method, combines the use of their appliances with specific therapeutic treatment protocols. The Vivos Method is estimated to be indicated and potentially effective in approximately 80% of OSA cases where patients comply with clinical treatments, within the scope of FDA cleared uses. Vivos's patented C.A.R.E. oral appliances have been used by approximately 60,000 patients treated worldwide by over 2,000 trained dentists. Their other lines of oral appliances have treated an estimated additional 15,000 or more patients globally. Since 2024, the company has been shifting its business model to generate revenue from appliance sales and the provision of healthcare services. This involves acquiring and managing sleep medical practices that diagnose and treat OSA, and establishing Vivos-supported and managed Dental and Medical Service Organizations (DSOs and MSOs). The company has started branding its OSA treatment business as Sleep and Airway Medicine Centers (SAMC). The Vivos Method now includes a broader range of product and service lines beyond the proprietary technologies in their C.A.R.E. appliances.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors VVOS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Vivos Therapeutics Secures $4.6M via Warrant Inducement, Issues New Dilutive Warrants
  • Vivos Therapeutics Secures Up to $5.5M Convertible Note with 10% Discount for Working Capital
  • Vivos Therapeutics Registers 1.98M Shares for Resale by Institutional Investor, Signaling Potential Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$17.44M
Net Income
-$21.17M
Diluted EPS
-$2.07
Op. Cash Flow
-$15.26M
Free Cash Flow
-$17.6M
Gross Profit
$10.54M
Operating Income
-$19.89M
Cash & Equivalents
$2.03M
Total Debt
$8.82M
Debt / Equity
-5.92×
Net Margin
-121.4%
Shares Outstanding
9.29M sh
Source: 10-K · filed 2026-04-15 · accession 0001493152-26-016854
$0.49 -0.01% today
52-week range · as of 2026-06-16 $0.5151 – $7.95
Market cap
$6.95M
Volume
500.6K (0.2× avg)
3-mo avg 2.7M
Live data · 2026-06-19 08:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VVOS - Filings & News (Page 2)

VVOS
Jan 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $0.490 info
Change: -$1.48 (-75%) info
Market Cap: $6.947M info
VVOS
Jan 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.06
Real-time Price: $0.490 info
Change: -$1.57 (-76%) info
Market Cap: $6.947M info
VVOS
Jan 14, 2026, 4:05 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $2.09
Real-time Price: $0.490 info
Change: -$1.60 (-77%) info
Market Cap: $6.947M info